News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Side-effects news

Show

From To
Kidney problems
Analysis Backs New Tenofovir’s Kidney Safety Over Old Version

Researchers compared data on more than 9,000 people with HIV who took either version of tenofovir.

Published
11 July 2019
From
POZ
Side-effects
Cases of hair loss among African-American women reported after switch to new tenofovir formula

Hair loss (alopecia) occurred in six African-American women living with HIV after switching to the new formula of tenofovir, clinicians report in Open Forum Infectious Diseases. The

Published
26 June 2019
By
Michael Carter
Side-effects
Major HIV drug calls for vigilance

A study lead by researchers at the Institute of HIV Research, Medical Faculty of UDE and University Hospital Essen, stumbled over a potential toxicity of integrase inhibitors. The researchers found that INSTI had a dramatic effect on activity of immune cells and in particular reduced the activity and function of CD4 T helper cells. This included a reduced proliferation and multiplication of these cells.

Published
24 June 2019
From
University of Duisberg-Essen
Child developmental issues
Antiretrovirals do not cause neurodevelopmental harm to uninfected infants

In the first five years of life the neurological development of HIV-exposed but uninfected infants, exposed to maternal antiretrovirals before and after birth and throughout breastfeeding, is comparable

Published
24 June 2019
By
Carole Leach-Lemens
Treatment-experienced people
ART for treatment-experienced people with virological failure can omit NRTIs if three active drugs available

Treatment for HIV-positive individuals with persistent viral replication despite therapy with multiple regimens is effective and safe over two years when it omits nucleoside reverse transcriptase inhibitors

Published
13 June 2019
By
Michael Carter
Side-effects
Preventing Drug Induced Liver Injury in Patients with HIV

With an estimated annual incidence rate of 13.9 to 24 per 100,000 inhabitants, drug-induced liver injury (DILI) the leading cause of acute liver failure in the United States. It is also a unique concern in people living with HIV. Recognizing the importance of comorbid HIV and DILI, researchers from Sacco University Hospital in Milano, Italy, have published a comprehensive review of the topic ahead-of-print in the journal Pharmacological Research.

Published
03 June 2019
From
Pharmacy Times
Side-effects
A Promising Anti-HIV Drug Poses A Dilemma

The anti-HIV drug dolutegravir is effective — but may carry a risk for pregnant women. While women in wealthy countries are given choices about their medical care, for women in poor countries the situation is different. There aren't enough doctors and nurses to explain the risks and benefits of the new drug to every patient. The country may not have the resources to keep supplies of two different drugs on the shelves. And there is no consistent access to effective birth control.

Published
23 April 2019
From
NPR
Side-effects
Weight gain with new antiretrovirals: It's complicated

South Africa’s next big shift in our antiretroviral programme is to replace efavirenz with a newish drug called dolutegravir. The Department of Health is pleased at the prospect of a safer, more robust and, amazingly, cheaper drug. But last year, the first reports surfaced that people using it were gaining weight.

Published
15 April 2019
From
Spotlight
Side-effects
Gilead Lawsuits: 41 HIV and PrEP Patients File California Personal Injury Case Over Gilead's TDF-Based Drugs

41 patients from 12 states nationwide who are living with HIV or AIDS or were on PrEP filed a personal injury lawsuit against Gilead Sciences Inc. seeking to hold the Bay Area drug maker accountable for actions around its failure to rectify a known defect in the drug formulation of one of its most widely prescribed medications: tenofovir disoproxil fumarate (TDF) knowing that a safer alternate, tenofovir alafenamide (TAF) existed in its own laboratory; its failure to warn patients of the damaging side effects of TDF; and the company’s active misrepresentation of TDF’s efficacy and substantial risks.

Published
12 April 2019
From
Associated Press
Side-effects
HIV Drugs With Fewer Side Effects Need More FDA Support

New medicines providing a better quality of life should always be top priority when asking for federal support.

Published
27 March 2019
From
HivPlusMag.com
← First12345...84Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.